Your browser is no longer supported. Please, upgrade your browser.
DMTK DermTech, Inc. daily Stock Chart
DermTech, Inc.
Index- P/E97.30 EPS (ttm)0.14 Insider Own14.40% Shs Outstand12.03M Perf Week-0.89%
Market Cap160.36M Forward P/E- EPS next Y-1.89 Insider Trans0.00% Shs Float6.74M Perf Month1.99%
Income0.70M PEG- EPS next Q-0.40 Inst Own39.10% Short Float1.27% Perf Quarter52.71%
Sales2.40M P/S66.70 EPS this Y396.40% Inst Trans-5.94% Short Ratio1.40 Perf Half Y-36.35%
Book/sh1.09 P/B12.23 EPS next Y39.00% ROA0.90% Target Price15.00 Perf Year-33.81%
Cash/sh0.00 P/C- EPS next 5Y- ROE1.00% 52W Range4.52 - 23.24 Perf YTD7.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.64% Beta-
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low194.91% ATR1.02
Employees36 Current Ratio0.00 Sales Q/Q-11.90% Oper. Margin- RSI (14)51.85 Volatility8.77% 7.91%
OptionableNo Debt/Eq0.00 EPS Q/Q-19.60% Profit Margin- Rel Volume0.46 Prev Close12.99
ShortableYes LT Debt/Eq0.00 EarningsMar 05 Payout0.00% Avg Volume61.16K Price13.33
Recom2.00 SMA20-0.28% SMA506.81% SMA200-1.39% Volume27,737 Change2.62%
Dec-05-19Initiated Lake Street Buy
Feb-11-20 05:29PM  DermTech to Present at Upcoming Investor Conferences Business Wire
Feb-10-20 03:06PM  Cowens Tim Manning at 2nd SPAC Roundtable: Fundamental Investor Interest in SPACs On Rise
Jan-16-20 05:45PM  DermTech Enters into Commercial and Medicare Advantage Payor Coverage Contract for the Pigmented Lesion Assay Business Wire
Jan-08-20 08:00AM  CMS Releases Final 2020 Clinical Lab Fee Schedule (CLFS) Including Pricing for DermTechs Pigmented Lesion Assay (PLA) Business Wire -10.88%
Jan-02-20 08:00AM  DermTechs Pigmented Lesion Assay (PLA) Receives Medicare Coverage Business Wire
Nov-07-19 01:30PM  DermTech, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire +6.89%
Nov-06-19 02:28PM  DermTech to Present at Upcoming Investor Conferences Business Wire
Oct-28-19 08:00AM  DermTech Receives CPT® Proprietary Laboratory Assay Code from the American Medical Association Business Wire
Oct-22-19 08:00AM  DermTech Presents New Data at Fall Clinical Dermatology Conference Business Wire -9.28%
Oct-18-19 04:15PM  DermTech Announces Common Stock Will Continue Trading on The Nasdaq Capital Market; Warrant Delisting from The Nasdaq Capital Market Business Wire
Oct-15-19 08:00AM  DermTechs Test Included in Expert Panels Clinical Management Recommendations for Cutaneous Melanoma Business Wire
Oct-07-19 08:00AM  DermTech Further Expands Patent Portfolio Business Wire
Sep-16-19 04:30PM  DermTech Announces Appointment of Kevin Sun as Chief Financial Officer Business Wire
DermTech, Inc. develops and markets novel non-invasive gene expression tests for diagnosis of various skin conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PANCOAST SCOTT RDirectorFeb 07Option Exercise1.083,9904,30933,874Feb 11 04:09 PM
PANCOAST SCOTT RDirectorFeb 05Option Exercise1.083,9904,30929,884Feb 07 04:17 PM